Zofran: Clinical Trials

18 trials of Zofran, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 2 terminated. 18 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Completed 16, Terminated 2
Phase 23Completed 3

Follow Zofran: new trials by email Literature Review of Zofran trials Research Report on Zofran

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human
Phase 1TerminatedNational Cancer Institute (NCI)362022-03-082025-12-02
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
PLX038, Rucaparib, Ondansetron - Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)102020-04-082026-08-26
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
Bremelanotide, Zofran, Placebo - Nausea
Phase 1CompletedAMAG Pharmaceuticals, Inc.2282019-06-172022-04-04
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
LMP744, Ondansetron, Olanzapine - Solid Tumors, Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)362017-02-272024-12-10
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
E7 TCR cells, Aldesleukin, Fludarabine - Papillomavirus Infections, Cervical Intraepithelial Neoplasia
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)2242017-01-272026-03-09
The Effects of Ondansetron on Brain Function
ondansetron, placebo - Brain Function, Healthy Adults
Phase 1CompletedIcahn School of Medicine at Mount Sinai542015-08-012017-04-11
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
Ondansetron with1:1 ORA - sweet. - Gastroenteritis
Phase 1CompletedHamad Medical Corporation402014-09-012015-06-17
Ondansetron for Pediatric Mild Traumatic Brain Injury
Ondansetron, PLacebo - Traumatic Brain Injury, Brain Concussion
Phase 1CompletedSt. Justine's Hospital162013-03-012015-09-29
How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women
Ondansetron - Postoperative Nausea
Phase 1 / Phase 2CompletedStanford University1002013-01-012015-06-01
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
Ondansetron, Ondansetron + Hylenex, Zofran ODT - Healthy
Phase 1CompletedHalozyme Therapeutics122012-02-012014-01-24
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
ondansetron, moxifloxacin, saline - Nausea and Vomiting, Chemotherapy-Induced
Phase 1CompletedGlaxoSmithKline602011-08-162017-11-13
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron - Chemotherapy-Induced Nausea and Vomiting
Phase 1TerminatedMerck Sharp & Dohme LLC922009-02-052018-09-25
A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
Aprepitant, Ondansetron - Postoperative Nausea and Vomiting
Phase 1CompletedMerck Sharp & Dohme LLC982009-01-262021-01-26
Two Way Bioequivalence Study Under Fed Conditions
Ondansetron (ODFS), Ondansetron (ODT) - Healthy
Phase 1CompletedMonoSol Rx482008-10-012017-05-02
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
SCH 727965, Aprepitant, Ondansetron - Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1CompletedMerck Sharp & Dohme LLC812006-10-112017-10-23
Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions
Ondansetron, Zofran - Healthy
Phase 1CompletedPar Pharmaceutical, Inc.242003-10-012008-04-16
Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions
Ondansetron, Zofran - Healthy
Phase 1CompletedPar Pharmaceutical, Inc.322002-08-012008-04-11
Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions
Ondansetron, Zofran - Healthy
Phase 1CompletedPar Pharmaceutical, Inc.182002-08-012008-04-11

Conditions studied

Vomiting (3)  ·  Fasting (2)  ·  Nausea (2)  ·  Postoperative Nausea and Vomiting (2)  ·  Brain Concussion (1)  ·  Brain Injuries, Traumatic (1)  ·  Carcinoma (1)  ·  Carcinoma in Situ (1)  ·  Emergencies (1)  ·  Gastroenteritis (1)  ·  Lecithin Cholesterol Acyltransferase Deficiency (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Neoplasm Metastasis (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  Merck Sharp & Dohme LLC (3)  ·  Par Pharmaceutical, Inc. (3)  ·  AMAG Pharmaceuticals, Inc. (1)  ·  GlaxoSmithKline (1)  ·  Halozyme Therapeutics (1)  ·  Hamad Medical Corporation (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  MonoSol Rx (1)  ·  St. Justine's Hospital (1)  ·  Stanford University (1)

Countries

United States (10)  ·  Canada (2)  ·  Brazil (1)  ·  India (1)  ·  Mexico (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)

Top investigators

Christian Aumais (2)  ·  Scott M Norberg, D.O. (2)  ·  Alice P Chen, M.D. (1)  ·  David R. Drover, MD (1)  ·  Emily Stern, PhD (1)  ·  Eric Sicard (1)  ·  James Gulley, M.D. (1)  ·  Jocelyn Gravel, MD (1)  ·  Khalid Al-Ansari, MD, FRCPC, FAAP (1)  ·  Samuel S Dychter, MD (1)  ·  Sudershan Vishwanath (1)

Results publications

PMID 23053255, PMID 24486335, PMID 25670522, PMID 25770814, PMID 28859059, PMID 32839657, PMID 33558725, PMID 40439882, PMID 40856942

NIH funding

2008 (1)